Search results
Professor Aimin Xu is currently a Professor in the Department of Medicine, School of Clinical Medicine and also the director for State Key Laboratory of Pharmaceutical Biotechnology (www.sklpb.hku.hk) at the University of Hong Kong.
Aimin Xu is currently a Chair Professor jointly appointed by the Department of Medicine and the Department of Pharmacology & Pharmacy, and also the director for State Key Laboratory of Pharmaceutical Biotechnology (www.sklpb.hku.hk) at the University of Hong Kong.
Our primary research interest is to investigate the role of adipokines in the pathogenesis of obesity-related insulin resistance, systemic inflammation, T2DM and vascular dysfunctions in animal models and human subjects.
Professor Aimin Xu and his research associates Research Interests Obesity is a major risk factor of type 2 diabetes (T2DM), insulin resistance and cardiovascular diseases (CVDs).
Adiponectin attenuates allergen-induced airway inflammation and hyperresponsiveness in mice. AWK Tso, A Xu, PC Sham, NMS Wat, Y Wang, CHY Fong, BMY Cheung, ...
Aimin XU | Cited by 36,452 | of The University of Hong Kong, Hong Kong (HKU) | Read 711 publications | Contact Aimin XU
Xu Aimin-CV My laboratory also identified and characterized several other novel adipokines and hepatokines, including adipocyte fatty acid binding protein (A-FABP), FGF21, Angptl4 and lipocalin2.
